Executive Summary
Summary Simcere Pharmaceutical Group (Simcere) is a pharmaceutical company which discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas such as anti-tumor, central nervous, anti-infection, cardiovascular, skeletal muscle, and others. Its product portfolio includes recombinant human endostatin injection, nedaplatin for injection, palonosetron hydrochloride injection, fluorouracil implants and lyvamlodipine besylate tablets, among others. Simcere's products are used for the treatment of oncology, neurology, infectious diseases, anti-inflammation and cardiovascular diseases. The company conducts research and development focused on low end generics and APIs to innovative medicines. The company's precision medicine sector, Simcere Diagnotics had strategic partnership t with Agena Bioscience,focused on Agena's MassARRAY System for companion diagnostics and pharmacogenetic testing in China. Simcere is headquartered in Nanjing, Jiangsu, China. Simcere Pharmaceutical Group-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios. - Business Description-A brief description of the company's operations. - Key Employees-A list of the key executives of the company. - Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors-A list of the key competitors of the company. - Key Recent Developments-A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.
Read More
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
Table of Contents Table of Contents 3 List of Tables 4 List of Figures 4 Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6 Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8 Simcere Pharmaceutical Group, Medical Devices Deals, 2012 to YTD 2018 10 Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11 Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deal Details 12 Partnerships 12 Amgen and Simcere Pharma Enter into Co-Development Agreement 12 Simcere Pharma Enters into Agreement with Daiichi Sankyo 13 Simcere Pharma Enters into Agreement with Celon Pharma 14 Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 15 Licensing Agreements 17 HitGen Enters into Licensing Agreement with Simcere Pharma 17 Simcere Pharma to Enter into Licensing Agreement with Merus 18 Acquisition 19 Jinsheng Ren And Assure Ahead Investments Completes Acquisition Of Simcere Pharma For USD 517 Million In Going Private Transaction 19 Zhuhai Rongding Acquires Jilin Boda Pharma From Simcere Pharma 21 Devont Asset Management To Acquire 35% Stake In Shanghai Celgen From Simcere Pharma For USD 48 Million 22 Simcere Pharmaceutical Group-Key Competitors 23 Simcere Pharmaceutical Group-Key Employees 24 Simcere Pharmaceutical Group-Locations And Subsidiaries 25 Head Office 25 Other Locations & Subsidiaries 25 Recent Developments 27 Strategy And Business Planning 27 Apr 02, 2018: Simcere announced establishment of Simcere Innovation Center 27 Legal and Regulatory 28 Aug 14, 2017: Minister of Industry and Information Technology Inspected Simcere 28 May 24, 2017: Miao Ruilin, Mayor of Nanjing, investigated Simcere Dongyuan Production Base of Anti-cancer and Anti-Cardiovascular and Cerebrovascular Medicines 29 Other Significant Developments 30 Apr 11, 2018: Shaanxi and Jiangsu top provincial leadership team went on inspection tour in Simcere headquater 30 Appendix 31 Methodology 31 About GlobalData 31 Contact Us 31 Disclaimer 31
List of Tables Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Key Facts 2 Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6 Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 Simcere Pharmaceutical Group, Deals By Therapy Area, 2012 to YTD 2018 8 Simcere Pharmaceutical Group, Medical Devices Deals, 2012 to YTD 2018 10 Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11 Amgen and Simcere Pharma Enter into Co-Development Agreement 12 Simcere Pharma Enters into Agreement with Daiichi Sankyo 13 Simcere Pharma Enters into Agreement with Celon Pharma 14 Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 15 HitGen Enters into Licensing Agreement with Simcere Pharma 17 Simcere Pharma to Enter into Licensing Agreement with Merus 18 Jinsheng Ren And Assure Ahead Investments Completes Acquisition Of Simcere Pharma For USD 517 Million In Going Private Transaction 19 Zhuhai Rongding Acquires Jilin Boda Pharma From Simcere Pharma 21 Devont Asset Management To Acquire 35% Stake In Shanghai Celgen From Simcere Pharma For USD 48 Million 22 Simcere Pharmaceutical Group, Key Competitors 23 Simcere Pharmaceutical Group, Key Employees 24 Simcere Pharmaceutical Group, Subsidiaries 25
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Simcere Pharmaceutical Group, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
|
Agriculture and Animal Care
Automotive, Transportation and Warehousing
Banking Financial Services and Insurance
Consumer Products and Retail
Defense and Security
Education and Recruitment
Energy and Utilities
Food, Beverage and Tobacco
Healthcare
Manufacturing and Construction
Media and Entertainment
Metal, Mining and Chemicals
Public Sector and Administration
Technology and Telecom
